Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Daridorexant, ATC N05CJ03 für die Zeit 01.06.2026 - 31.05.2028

Section 130a, paragraph 8, SGB V enables health insurance funds and pharmaceutical companies to conclude framework discount contracts for medicines to be dispensed at the expense of the statutory health insurance funds. With regard to the relevant legal provisions for the award of public contracts, the DAK-Gesundheit regularly conducts substance-related, formal tendering procedures according to the regulations of Part 4 of the GWB. For medicines to be specified by the bidder in more detail in Annex 2 to the contract, for the aforementioned substance Daridorexant, ATC N05CJ03, the DAK-Gesundheit intends to conclude discount contracts for medicines with as many interested pharmaceutical companies as possible until the entry into force of new medicine discount contracts. A discount contract under the authorisation model for the aforementioned substance will enter into force for the first time on 01.06.2026 and will end on 31.05.2028. It will end automatically with the entry into force of the exclusive contract, regardless.